January 31, 2023 10:37 AM ESTUpdated 02:42 PM
Deals

Gilead quash­es mi­cro­cap biotech's hope of part­ner­ing on oral Covid-19 drug

Amber Tong

Gilead is call­ing it quits on a two-year-old project to de­vel­op an oral for­mu­la­tion of its Covid-19 an­tivi­ral remde­sivir, its biotech coun­ter­parts at Mati­nas Bio­Phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

A service from the Financial Times